# US 11,998,644 B2 · Dry pad > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,998,644 B2 - Document ID: US11998644B2 - Status: Granted - Kind: B2 - Application number: 15/768,300 - Filed: 2016-10-17 - Published: 2018-10-25 - Granted: 2024-06-04 - Earliest claimed: 2015-10-16 - Assignees: Amolifescience Co., Ltd. - Applicants: Amolifescience Co., Ltd. - Inventors: In Yong Seo; Ji Hyun Lee - Web page: https://patentgrep.com/patent/US11998644B2 ## CPC - A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)} - A61F 13/00: Bandages or dressings (radioactive dressings {A61N5/1029}); Absorbent pads - A61F 13/00063: {comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic (drug delivery dressings A61K9/70; chemical aspect of the additives A61L15/00)} - A61F 13/01017: {synthetic, e.g. polymer based} - A61F 13/01029: {made of multiple layers} - A61K 33/38: Silver; Compounds thereof - A61K 38/43: Enzymes; Proenzymes; Derivatives thereof - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61L 15/42: Use of materials characterised by their function or physical properties (liquid bandages A61L26/00) - A61L 15/44: Medicaments - A61L 15/46: Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria - A61L 15/60: Liquid-swellable gel-forming materials, e.g. super-absorbents - D04H 1/728: by electro-spinning {(electro-spinning methods and apparatus D01D5/0007)} - A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) - A61L 2300/104: Silver, e.g. silver sulfadiazine - A61L 2300/254: Enzymes, proenzymes - A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents - A61L 2300/414: Growth factors - A61L 2300/428: Vitamins, e.g. tocopherol, riboflavin - A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - D04H: MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL (weaving D03; knitting D04B; braiding D04C; net-making D04G; sewing D05B; tufting D05C; finishing non-woven fabrics D06); FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING {; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION}(non-woven fabrics having an intermediate or external layer of a different kind, e.g. of woven fabric, B32B) ## Abstract Provided is a dry pad, including a wound-covering membrane formed by arranging a fiber containing a hydrophilic polymer that is swollen by an exudate secreted from a wound, a hydrophobic polymer, and a dry wound-healing agent that is released through swelling of the hydrophilic polymer and is difficult to store in a liquid phase, and a first release member, which is a support on which the fiber is arranged and which is separated from the wound-covering membrane. ## Claims ### Claim 1 A dry pad, comprising: a wound-covering membrane; and a first release member on which the wound-covering membrane is disposed, wherein the first release member is configured to be able to be separated from the wound-covering membrane, wherein the wound-covering membrane comprises: at least two layers of wound-covering membranes, the at least two layers of wound-covering membranes each being formed of electrospun fibers, wherein each of the electrospun fibers is made of a solution consisting of a hydrophilic polymer, a hydrophobic polymer, and a dry wound-healing agent, wherein the hydrophilic polymer is configured to be swollen by an exudate secreted from a wound of a user, and the dry wound-healing agent is configured to be released towards the wound through swelling of the hydrophilic polymer, and wherein, in the at least two layers of wound-covering membranes, a content of the hydrophilic polymer gradually increases towards the wound so as to achieve rapid swelling by the exudate. ### Claim 2 (depends on 1) The dry pad of claim 1, wherein the dry wound-healing agent is any one selected from the group consisting of a vitamin, an enzyme, a protein, and a peptide-vitamin C derivative. ### Claim 3 (depends on 1) The dry pad of claim 1, further comprising: a second release member, wherein the first release member is disposed on a surface of the wound-covering membrane, and the second release member is formed on the other surface of the wound-covering membrane. ### Claim 4 (depends on 1) The dry pad of claim 1, wherein the wound-healing agent contains at least one selected from the group consisting of an epidermal growth factor, a fibroblast growth factor, a protein for healing, and an antimicrobial material. ### Claim 5 (depends on 4) The dry pad of claim 4, wherein the antimicrobial material is any one selected from the group consisting of a silver nanomaterial, silver particles, and a natural antimicrobial material. ### Claim 6 (depends on 5) The dry pad of claim 5, wherein the silver nanomaterial is any one selected from the group consisting of silver nitrate (AgNO3), silver sulfate (Ag2SO4), and silver chloride (AgCl). ### Claim 7 (depends on 5) The dry pad of claim 5, wherein the silver particles have a size smaller than a diameter of the electrospun fibers. ### Claim 8 (depends on 1) The dry pad of claim 1, wherein the hydrophilic polymer includes any one selected from the group consisting of PU (polyurethane) and hydrogel. ### Claim 9 (depends on 1) The dry pad of claim 1, wherein the first release member is any one selected from the group consisting of a release film, release paper, and a nonwoven fabric. ### Claim 10 (depends on 1) The dry pad of claim 1, wherein the electrospun fibers have a diameter of 0.2 to 1.5 μm. ### Claim 11 (depends on 1) The dry pad of claim 1, wherein the hydrophilic polymer and the hydrophobic polymer are mixed at a weight ratio of 3:7 to 9:1. ### Claim 12 (depends on 11) The dry pad of claim 11, wherein the dry wound-healing agent is used in an amount of 0.1 to 15 wt % based on a total weight of the hydrophilic polymer and the hydrophobic polymer. ### Claim 13 (depends on 12) The dry pad of claim 12, wherein the dry wound-healing agent includes a vitamin, and the vitamin is used in an amount of 5 to 10 wt % based on the total weight of the hydrophilic polymer and the hydrophobic polymer. ### Claim 14 (depends on 1) The dry pad of claim 1, wherein the dry wound-healing agent is linked to or contained in a hydrophilic polymer chain of the hydrophilic polymer and incorporated into the electrospun fibers, and when the hydrophilic polymer absorbs water of the exudate and swells, particles of the dry wound-healing agent are released.